The Zhitong Finance App learned that long-term data from two phase 3 clinical trials of Johnson & Johnson (JNJ.US) showed that adult patients with Crohn's disease treated with Tremfya (guseciumab) had a clinical remission rate of up to 94% within three years.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.